Hemlibra (emicizumab)

Hemlibra is manufactured in Switzerland and shipped by courier from our pharmacy in India.

Information about Hemlibra

Hemlibra is a recombinant bispecific monoclonal antibody designed for the treatment of hemophilia A, particularly in patients with inhibitors to factor VIII. It mimics the function of factor VIII, promoting effective blood clotting.

Product Highlights

• Indicated for the prophylaxis of bleeding episodes in patients with hemophilia A, including those with or without factor VIII inhibitors.

Key Ingredient

• Emicizumab

Key Benefits

• Demonstrated efficacy in reducing the frequency of bleeding episodes in patients with hemophilia A.
• Provides a more predictable and stable treatment option, enhancing daily living and reducing treatment burden.
• Can be used in patients with inhibitors who do not respond to traditional factor VIII replacement therapies.

Direction of Use

• Administered subcutaneously; healthcare providers typically instruct on self-administration techniques.
• Initial dosing usually involves a loading dose, followed by maintenance doses based on the prescribed schedule (weekly, biweekly, or every four weeks).
• Regular follow-ups are necessary to assess efficacy and any potential adverse effects.

Safety Concerns

• May include injection site reactions, headache, and fatigue.
• There is a potential risk of thrombotic events, particularly in patients with certain risk factors; monitoring is essential.
• Some patients may develop antibodies against emicizumab, which can affect treatment efficacy.

Avoid Hemlibra (Emicizumab) If

• Known allergy to emicizumab or any components of the formulation.
• Patients with a history of or active thromboembolic disease should avoid use due to increased risk.
• Caution is advised for patients with severe renal dysfunction; consult a healthcare provider for alternatives.
• Avoid in patients with active infections or those who are immunocompromised, as safety in these populations has not been fully established.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.